Besides ibrutinib, sufferers with M-CLL, devoid of TP53 aberrations and fit plenty of to tolerate FCR therapy, should still be superior candidates to the latter, With all the gain currently being this cure could be completed in 6 months when ibrutinib must be taken indefinitely. This option would be especially important for non-compliant sufferers